[go: up one dir, main page]

HUP0100397A2 - Tetrahidro- vagy oktahidrobenzo-naftiridin és kinolinszármazékok, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra - Google Patents

Tetrahidro- vagy oktahidrobenzo-naftiridin és kinolinszármazékok, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra

Info

Publication number
HUP0100397A2
HUP0100397A2 HU0100397A HUP0100397A HUP0100397A2 HU P0100397 A2 HUP0100397 A2 HU P0100397A2 HU 0100397 A HU0100397 A HU 0100397A HU P0100397 A HUP0100397 A HU P0100397A HU P0100397 A2 HUP0100397 A2 HU P0100397A2
Authority
HU
Hungary
Prior art keywords
group
optionally substituted
general formula
optionally
aromatic
Prior art date
Application number
HU0100397A
Other languages
English (en)
Inventor
Ben C. Askew
Paul J. Coleman
Mark E. Duggan
Wasyl Halczenko
George D. Hartman
Cecilia Hunt
John H. Hutchinson
Robert S. Meissner
Michael A. Patane
Garry R. Smith
Jiabing Wang
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9807382.8A external-priority patent/GB9807382D0/en
Priority claimed from GBGB9811295.6A external-priority patent/GB9811295D0/en
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of HUP0100397A2 publication Critical patent/HUP0100397A2/hu
Publication of HUP0100397A3 publication Critical patent/HUP0100397A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Resistance Heating (AREA)

Abstract

A találmány tárgyát (B) általános képletű vegyületek és sóik, ezekettartalmazó gyógyszerkészítmények és ezek előállítása képezi.Közelebbről, a találmány szerinti vegyületek az av<3, az av<5 és/vagyav<6 integrin receptorok antagonistái, és csontfelszívódás gátlásában,oszteoporózis kezelésére vagy megelőzésére, ér-újrabeszűkülés,diabéteszes retinopátia, makuladegenerálódás, angingenezis,ateroszklerózis, gyulladások, vírusfertőzések, tumornövekedés és -áttét gátlására és sebgyógyulás kezelésére alkalmazhatók. A találmányszerinti vegyületek (B) általános képletében X jelentése (1) általánosképletű csoport, 5- vagy 6-tagú monociklusos aromás vagy nem-aromás,adott esetben heteroatomot tartalmazó és adott esetben helyettesítettgyűrűrendszer, vagy 9-14-tagú policiklusos, adott esetben heteroatomottartalmazó és adott esetben helyettesített gyűrűrendszer, amelyben agyűrűk közül egy vagy több aromás; Y jelentése adott esetben egy vagytöbb oxigén, nitrogén és/vagy kén heteroatomot tartalmazó, adottesetben helyettesített telített lineáris szénhidrogénlánc; Z jelentése(3), (4) vagy (5) általános képletű csoport, vagy adott esetbenhelyettesített -CH2CH2- vagy -CH=CH- csoport; R5, R6, R7 és R8jelentése egymástól függetlenül többek között hidrogénatom, alkil-vagy arilcsoport, halogénatom, hidroxilcsoport, alkenil- vagyalkinilcsoport, adott esetben oxigén-, nitrogén- és/vagy kénatomottartalmazó, adott esetben helyettesített telített vagy telítetlenszénhidrogénlánc, és további helyettesített amino- és alkilcsoportok;R9 jelentése hidrogénatom, arilcsoport vagy adott esetbenhelyettesített alkil-csoport. Ó
HU0100397A 1997-12-17 1998-12-14 Tetrahydro- or octahydrobenzonaphtyridin and quinolin derivatives, pharmaceutical compositions thereof and process for their preparation HUP0100397A3 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US6989997P 1997-12-17 1997-12-17
GBGB9807382.8A GB9807382D0 (en) 1998-04-06 1998-04-06 Vitronectin receptor antagonists
US8320998P 1998-04-27 1998-04-27
GBGB9811295.6A GB9811295D0 (en) 1998-05-26 1998-05-26 Vitronectin receptor antagonists
US9262298P 1998-07-13 1998-07-13
PCT/US1998/026484 WO1999031061A1 (en) 1997-12-17 1998-12-14 Integrin receptor antagonists

Publications (2)

Publication Number Publication Date
HUP0100397A2 true HUP0100397A2 (hu) 2001-09-28
HUP0100397A3 HUP0100397A3 (en) 2002-10-28

Family

ID=27517453

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0100397A HUP0100397A3 (en) 1997-12-17 1998-12-14 Tetrahydro- or octahydrobenzonaphtyridin and quinolin derivatives, pharmaceutical compositions thereof and process for their preparation

Country Status (25)

Country Link
EP (1) EP1040098B1 (hu)
JP (1) JP3585839B2 (hu)
KR (1) KR20010033248A (hu)
CN (1) CN1284944A (hu)
AT (1) ATE294163T1 (hu)
AU (1) AU739811B2 (hu)
BG (1) BG104605A (hu)
BR (1) BR9813769A (hu)
CA (1) CA2315220C (hu)
DE (1) DE69829996T2 (hu)
EA (1) EA002822B1 (hu)
EE (1) EE200000362A (hu)
ES (1) ES2241192T3 (hu)
GE (1) GEP20032921B (hu)
HR (1) HRP20000401A2 (hu)
HU (1) HUP0100397A3 (hu)
ID (1) ID24955A (hu)
IL (1) IL136495A0 (hu)
IS (1) IS5521A (hu)
NO (1) NO20003114L (hu)
NZ (1) NZ504893A (hu)
PL (1) PL341215A1 (hu)
SK (1) SK9192000A3 (hu)
TR (1) TR200002557T2 (hu)
WO (1) WO1999031061A1 (hu)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9805655D0 (en) 1998-03-16 1998-05-13 Celltech Therapeutics Ltd Chemical compounds
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
SK15592000A3 (sk) * 1998-04-16 2001-12-03 Texas Biotechnology Corporation N,n-disubstituované amidy, ktoré inhibujú viazanie integrínov na ich receptory
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
CA2338878A1 (en) * 1998-08-13 2000-02-24 Merck & Co., Inc. Integrin receptor antagonists
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
CN1589145A (zh) * 1999-06-02 2005-03-02 麦克公司 αv整联蛋白受体拮抗剂
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
CA2386030A1 (en) * 1999-10-04 2001-04-12 Merck & Co., Inc. Integrin receptor antagonists
AU7912600A (en) * 1999-10-06 2001-05-10 Basf Aktiengesellschaft Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy
US6407241B1 (en) 1999-11-08 2002-06-18 Merck & Co., Inc. Process and intermediates for the preparation of imidazolidinone αv integrin antagonists
GB2356630A (en) 1999-11-10 2001-05-30 Merck & Co Inc Intermediates used in the preparation of tetrahydronaphthyridine
ATE258177T1 (de) 1999-11-23 2004-02-15 Merck & Co Inc Verfahren für die herstellung und zwischenprodukte von tetrahydro-(1,8)- naphthyridin
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
EP1254116A4 (en) 2000-01-24 2003-04-23 Merck & Co Inc ALPHA V INTEGRIN RECEPTOR ANTAGONISTS
WO2001079173A2 (en) 2000-04-17 2001-10-25 Celltech R & D Limited Enamine derivatives as cell adhesion molecules
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
JP2004502762A (ja) 2000-07-07 2004-01-29 セルテック　アール　アンド　ディ　リミテッド 二環性ヘテロ芳香環を含有するインテグリンアンタゴニストとしてのスクエア酸誘導体
EP1305291A1 (en) 2000-08-02 2003-05-02 Celltech R&amp;D Limited 3-substituted isoquinolin-1-yl derivatives
WO2002022616A2 (en) * 2000-09-14 2002-03-21 Merck & Co., Inc. Alpha v integrin receptor antagonists
US6444680B1 (en) 2000-11-30 2002-09-03 Merck & Co., Inc. Amine salts of an integrin receptor antagonist
US6764842B2 (en) 2001-03-28 2004-07-20 Merck & Co., Inc. Enantioselective bioreduction for the preparation of integrin receptor antagonist intermediates
ES2366775T3 (es) 2001-04-24 2011-10-25 Merck Patent Gmbh POLITERAPIA UTILIZANDO AGENTES ANTIANGIOGÉNICOS Y TNF(alfa).
PE20030120A1 (es) 2001-06-19 2003-02-12 Merck & Co Inc Sal amina de un antagonista de receptor de integrin
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
GB0420424D0 (en) * 2004-09-14 2004-10-20 Ionix Pharmaceuticals Ltd Therapeutic compounds
ES2521679T3 (es) 2006-01-18 2014-11-13 Merck Patent Gmbh Terapia específica usando ligandos de integrinas para el tratamiento del cáncer
AU2008207095B2 (en) 2007-01-18 2013-08-29 Merck Patent Gmbh Specific therapy and medicament using integrin ligands for treating cancer
EP2268317B1 (en) 2008-03-14 2020-02-26 VisEn Medical, Inc. Integrin targeting agents and in vivo and in vitro imaging methods using the same
KR20120104491A (ko) 2009-05-25 2012-09-21 메르크 파텐트 게엠베하 암 치료를 위한 실렌기티드의 연속 투여
MY159151A (en) * 2009-12-04 2016-12-15 Nissan Chemical Ind Ltd 2-pyridone compounds
US8901144B2 (en) 2013-02-07 2014-12-02 Scifluor Life Sciences, Llc Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives
CN108690022B (zh) * 2013-02-07 2021-08-17 赛弗卢尔生命科学公司 氟化整联蛋白拮抗剂
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
HUE057203T2 (hu) * 2013-09-24 2022-04-28 Fujifilm Corp Új nitrogén-tartalmú vegyület vagy sója, vagy azok fémkomplexe
BR112016008276B1 (pt) 2013-10-25 2021-03-02 Novartis Ag derivados bicíclicos de piridila fundidos ao anel, seus usos e seu intermediário, e composição farmacêutica
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
BR112017017888A2 (pt) 2015-02-19 2018-04-10 Scifluor Life Sciences Inc derivados fluorados do ácido tetraidronaftiridinil nonanoico derivados e usos destes
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
MX2017012184A (es) * 2015-03-25 2018-01-09 Fujifilm Corp Metodo para manufacturar compuesto novedoso que contiene nitrogeno o sal del mismo e intermediario de manufacturacion del compuesto novedoso que contiene nitrogeno o sal del mismo.
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
US11192889B2 (en) * 2016-07-05 2021-12-07 The Rockefeller University Tetrahydronaphthyridinepentanamide integrin antagonists
TW201823208A (zh) 2016-09-07 2018-07-01 美商普萊恩醫療公司 N－醯基胺基酸化合物及其使用方法
LT3660004T (lt) 2016-10-11 2023-06-12 Arvinas Operations, Inc. Junginiai ir metodai, skirti tikslinei androgeno receptoriaus degradacijai
RU2022108080A (ru) 2017-02-28 2022-04-07 Морфик Терапьютик, Инк. Ингибиторы интегрина avb6
EP3760202A1 (en) 2017-02-28 2021-01-06 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
US10793564B2 (en) * 2018-03-07 2020-10-06 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
BR112020021949A2 (pt) * 2018-04-27 2021-01-26 Arrowhead Pharmaceuticals, Inc. ligantes dirigidos à integrina e seus usos
TWI841573B (zh) * 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
EP4086254B1 (en) 2018-08-29 2024-12-18 Morphic Therapeutic, Inc. Integrin inhibitors
PT3844162T (pt) * 2018-08-29 2025-03-28 Morphic Therapeutic Inc Inibidores da integrina alfa v beta6
WO2020047207A1 (en) * 2018-08-29 2020-03-05 Morphic Therapeutics, Inc. Inhibitors of (alpha-v)(beta-6) integrin
AU2020207050A1 (en) 2019-01-09 2021-06-17 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of HIF-2 alpha (EPAS1), compositions thereof, and methods of use
EP3952902A4 (en) 2019-04-08 2022-12-21 Pliant Therapeutics, Inc. DOSAGE FORMS AND THERAPY SCHEMES FOR AMINO ACID COMPOUNDS
WO2021127443A1 (en) 2019-12-19 2021-06-24 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
AU2021273458A1 (en) 2020-05-09 2022-12-01 Arvinas Operations, Inc. Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same
CN114507202B (zh) * 2022-01-26 2023-10-03 海南大学 一种桑辛素类化合物及其制备方法与应用
GB202209228D0 (en) 2022-06-23 2022-08-10 Univ Strathclyde Modified amino acids and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3843798A (en) * 1973-03-12 1974-10-22 Stanley Drug Products Inc Methods and compositions for inducing resistance to bacterial infections
FR2466252A2 (fr) * 1979-10-03 1981-04-10 Clin Midy Nouveaux produits ayant notamment des proprietes anticancereuses a base de chaine a de la ricine et d'une proteine
US5025025A (en) * 1989-06-28 1991-06-18 Ciba-Geigy Corporation (Arylsulfonamido- and pyridyl-)-substituted carboxylic acids and derivatives thereof and use for suppressing thromboxane activity
FR2658511B1 (fr) * 1990-02-16 1992-06-19 Union Pharma Scient Appl Nouveaux derives de benzimidazole et d'azabenzimidazole, antagonistes des recepteurs au thromboxane; leurs procedes de preparation, compositions pharmaceutiques les contenant.
EP0578745A1 (en) * 1991-04-04 1994-01-19 The Upjohn Company Phosphorus containing compounds as inhibitors of retroviruses
ATE158589T1 (de) * 1991-11-22 1997-10-15 Yeda Res & Dev Nicht-peptidische surrogate der arg-gly-asp sequenz und entsprechende pharmazeutische zusammensetzungen
US5252591A (en) * 1992-08-14 1993-10-12 G. D. Searle & Company Pyridinyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension
WO1994008577A1 (en) * 1992-10-14 1994-04-28 Merck & Co., Inc. Fibrinogen receptor antagonists
EP0737204A4 (en) * 1993-12-06 1999-06-23 Cytel Corp CS - 1 peptide mimetics, compositions and methods of their use
DE69528829T2 (de) * 1994-05-27 2003-08-07 Merck & Co., Inc. Präparate zur hemmung der durch osteoklasten vermittelten knochenresorption
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
DE69627899T2 (de) * 1995-06-29 2004-05-19 Smithkline Beecham Corp. Integrin-rezeptor-antagonisten
EP0880511A4 (en) * 1996-01-16 1999-06-16 Merck & Co Inc INTEGRIN RECEPTOR ANTAGONISTS

Also Published As

Publication number Publication date
BR9813769A (pt) 2000-10-10
EP1040098A1 (en) 2000-10-04
HRP20000401A2 (en) 2001-12-31
DE69829996T2 (de) 2006-02-23
NZ504893A (en) 2002-10-25
SK9192000A3 (en) 2001-03-12
EE200000362A (et) 2001-12-17
KR20010033248A (ko) 2001-04-25
EA200000660A1 (ru) 2001-02-26
TR200002557T2 (tr) 2000-12-21
IL136495A0 (en) 2001-06-14
WO1999031061A1 (en) 1999-06-24
ATE294163T1 (de) 2005-05-15
NO20003114D0 (no) 2000-06-16
PL341215A1 (en) 2001-03-26
ES2241192T3 (es) 2005-10-16
GEP20032921B (en) 2003-03-25
JP3585839B2 (ja) 2004-11-04
BG104605A (bg) 2001-05-31
EP1040098A4 (en) 2002-10-30
IS5521A (is) 2000-05-31
CA2315220A1 (en) 1999-06-24
EA002822B1 (ru) 2002-10-31
JP2002508355A (ja) 2002-03-19
AU739811B2 (en) 2001-10-18
CA2315220C (en) 2006-03-21
CN1284944A (zh) 2001-02-21
HUP0100397A3 (en) 2002-10-28
DE69829996D1 (de) 2005-06-02
EP1040098B1 (en) 2005-04-27
NO20003114L (no) 2000-08-16
AU1822099A (en) 1999-07-05
ID24955A (id) 2000-08-31

Similar Documents

Publication Publication Date Title
HUP0100397A2 (hu) Tetrahidro- vagy oktahidrobenzo-naftiridin és kinolinszármazékok, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
AR016762A1 (es) Compuestos del acido 4-bromo o 4-yodo fenilamino benzohidroxamico, formulaciones farmaceuticas y uso del mismo
HUP0105409A2 (hu) Csípőbél-epesav transzport és taurokolát felvétel inhibitor aktivitású 1,2-benzotiazepin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
SE9902987D0 (sv) Novel compounds
SE9904738D0 (sv) Novel compounds
NO307178B1 (no) Anilinderivater, anvendelse derav og farmasoeytisk blanding
HUP9903671A2 (hu) Gonadotropint leadó hormonok antagonistái,e vegyületeket tartalmazó gyógyászati készítmények,valamint azok előállítása
HUT67434A (en) Fluoroalkoxy-benzylamino derivatives of nitrogen containing heterocycles and pharmaceutical compositions containing them and process for their production
HUP9902121A2 (hu) Gonadotropin-leadó hormon antagonista hatású indolszármazékok és ezeket a vegyületeket tartalmazó gyógyszerkészítmények
HUP9901960A2 (hu) Kristályos ziprasidont tartalmazó gyógyszerkészítmények és eljárás ilyen kristályok előállítására
HUP0401009A2 (hu) 5-Hidroxitriptamin-6-ligandumokként alkalmazható 1-aril- vagy 1- alkil-szulfonilbenzazol-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
DE69429440D1 (de) Tricyclische sulfonamide-derivate zur inhibierung der g-protein funktion und fur die bekandlung von proliferativen erkrantungen
ES2104708T3 (es) Compuestos heterociclicos terapeuticos.
HUP9901079A2 (hu) 5- és 6-Tagú nitrogéntartalmú gyűrűs vegyületek, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
NO20022558L (no) 4-karboksyamino-2-etyl-1,2,3,4-tetrahydrokinolinkrystall som CETP inhibitor
SE0300120D0 (sv) Novel compounds
DZ1694A1 (fr) &#34;n-(2-Aminoethyl)-benzothialozones&#34;.
HU911301D0 (en) Process for producing 2,9-disubstituted 4h-pyrido(1,2a)-pyrimidine derivatives and pharmaceutical preparatives containing these compounds as active substance
DE69330282D1 (de) Chinolon und acridinon derivate zur behandlung der harninkontinenz
HUP0400156A2 (hu) Pirrolidinszármazékok, mint Xa faktor inhibítorok, előállításuk és ezeket tartalmazó gyógyszerkészítmények
ES8103078A1 (es) Procedimiento para preparar derivados de pirimidona
NO179974C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive piperidinforbindelser
ES8800214A1 (es) Procedimiento para preparar derivados de bencimidazol substituidos
HUP0301594A2 (hu) E-metanikotin diacilborkősav sóját tartalmazó gyógyászati készítmények és alkalmazásuk a központi idegrendszer rendellenességeinek kezelésére
DE60104986D1 (de) Xanthinderivate, zwischenprodukte und verwendung zur behandlung von osteoporosis